Title: Su1499 Safety of Endoscopy in Patients on Antiangiogenic Agents
Abstract: Antiangiogenic agents (AA) such as Bevacizumab and Aflibercep. tare inhibitors of vascular endothelial growth factors and offer survival benefit in combination with cytotoxic chemotherapy. Bevacizumab is approved for colorectal, ovarian, snon-small cell lung and renal cell cancer. Aflibercept is approved for colorectal cancer. Their use has expanded significantly in the last few years which has led to increase awareness of potential toxicities including the risk of gastrointestinal perforation (GIP) and gastrointestinal bleeding (GIB). While the mechanism is still debated it is thought that it either involves ulceration or delayed healing of a gastrointestinal (GI) injury. The general risk of spontaneous perforation is estimated to be around 2%. It is estimated that the risk of perforation after colorectal stenting while on Bevacizumab is tripled. It is currently recommended that these agents are held for 28 days before and after surgery. There is no clear data or recommendation on the safety of endoscopy. Data on adverse events occurring in patient undergoing endoscpy (endo) within 31 days of administration of AA is presented.
Publication Year: 2015
Publication Date: 2015-04-27
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot